Table 2 Clinical studies and results from immune strategies
From: Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
Immune-peptide | Clinical Study | Drug Combinations | Patient Characteristics (pts) | Results (pts%) |
|---|---|---|---|---|
BCR-ABL1 as specific antigen | ||||
e14a2 | PhaseI/II(125) | IM | CP in CyR (n = 19) | (68%) < 1-log BA mRNA |
e13a2, e14a2 | PhaseII(126) | IM | CP in CyR (n = 10) | (30%) < 1-log BA mRNA (30%) MMR (transient response) |
CMLVAXB2 (e13a2) CMLVAXB3 (e14a2) | PhaseII NCT00267085 | IM | CP in CyR (n = 10) | (30%) ↓< 1-log BA mRNA |
CMLVAX100 (e14a2) | PhaseII(127) | IM IFN | CP in SRD (all n = 16) IM (n = 10); IFN (n = 6) | IM: (50%) CyR and (30%) BA UD IFN: (83%) CyR |
CMLVAX100-GMCSF | PhaseII(128) | IM IFN | CP in MRD (n = 43) | (51%) ↓50% BA mRNA |
CMLb2a2–25 (e13a2) | Case Study(129) | – | CP in CyR | BA UD |
e13a2, e14a2 | PhaseII NCT00428077 | – | MRD (n = 4) | (100%) < 1-log BA mRNA |
e13a2 | PhaseII NCT00466726 | IM | CP in MRD | NDP |
e13a2 | PhaseII NCT00004052 | – | CP in HR | NDP |
LAAs | ||||
WT1 | Case Study(131) | IM | MRD | ↓ BA mRNA |
PhaseI/II NCT00004918 | – | CP | NDP | |
GVAX | (132) | IM | CyR (n = 19) | (68%) ↓ BA mRNA |
ICB | ||||
Ipilimumab Nivolumab | PhaseI NCT01822509 | – | CP | ongoing |